Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sage Therapeutics, Inc.    SAGE

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Sage Therapeutics : to Present at Morgan Stanley 18th Annual Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
09/01/2020 | 07:31am EDT

Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020 at 2:45 p.m. ET.

A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about SAGE THERAPEUTICS, INC.
10/23SAGE THERAPEUTICS : Announces Chief Executive Jeff Jonas to Undergo Scheduled Me..
AQ
10/22SAGE THERAPEUTICS : Announces Chief Executive Jeff Jonas to Undergo Scheduled Me..
BU
10/20SAGE THERAPEUTICS : to Report Third Quarter 2020 Financial Results on Thursday, ..
AQ
10/19SAGE THERAPEUTICS : to Report Third Quarter 2020 Financial Results on Thursday, ..
BU
10/16SAGE THERAPEUTICS : Announces Positive Interim, Topline Zuranolone Safety and To..
AQ
10/15SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
10/15SAGE THERAPEUTICS : Announces Positive Interim, Topline Zuranolone Safety and To..
BU
10/02SAGE THERAPEUTICS : Appoints Barry Greene to Board of Directors
AQ
10/01SAGE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Event..
AQ
10/01SAGE THERAPEUTICS : Appoints Barry Greene to Board of Directors
BU
More news
Financials (USD)
Sales 2020 8,21 M - -
Net income 2020 -521 M - -
Net cash 2020 714 M - -
P/E ratio 2020 -7,33x
Yield 2020 -
Capitalization 3 814 M 3 814 M -
EV / Sales 2020 378x
EV / Sales 2021 167x
Nbr of Employees 675
Free-Float 98,1%
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 81,85 $
Last Close Price 73,38 $
Spread / Highest target 166%
Spread / Average Target 11,5%
Spread / Lowest Target -52,3%
EPS Revisions
Managers
NameTitle
Jeffrey M. Jonas President, Chief Executive Officer & Director
Kevin Paul Starr Chairman
Michael Cloonan Chief Operating Officer
Kimi E. Iguchi Chief Financial Officer & Treasurer
Albert J. Robichaud Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
SAGE THERAPEUTICS, INC.1.65%3 814
LONZA GROUP AG57.19%45 022
IQVIA HOLDINGS INC.-0.34%29 650
SEAGEN INC.45.98%29 023
CELLTRION, INC.33.15%28 374
MODERNA, INC.244.94%26 623